Daily Watch List: Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM), E Petroleo Brasileiro Petrobras SA (NYSE:PBR), Pacira Pharmaceuticals (NASDAQ:PCRX)


Recro Pharma, Inc. (NASDAQ:REPH) shares moved down -1.01% in last trading session and ended the day at $5.89. REPH Gross Margin is 44.90% and its has a return on assets of -14.70%. Recro Pharma, Inc. (NASDAQ:REPH) quarterly performance is -35.35%.

On 24 March, Recro Pharma, Inc. (NASDAQ:REPH) reported financial results for the year ended December 31, 2015. As of December 31, 2015, Recro Pharma had cash and cash equivalents of $19.8 million.

Stryker Corporation (NYSE:SYK) ended the last trading day at $106.87. Company weekly volatility is calculated as 1.34% and price to cash ratio as 9.78. Stryker Corporation (NYSE:SYK) showed a weekly performance of 1.92%.

Stryker Corporation (NYSE:SYK) announced that its 2016 Annual Meeting of Shareholders on
April 27, 2016 – 2:00 p.m. Eastern Time.

On 29 March, Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) shares moved up 1.33% and was closed at $25.97. TSM EPS growth in last 5 year was 13.40%. Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) year to date (YTD) performance is 14.15%.

On 16 March, ARM and Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) announced a multi-year agreement to collaborate on a 7nm FinFET process technology which includes a design solution for future low-power, high-performance compute SoCs. The new agreement expands the companies’ long-standing partnership and advances leading-edge process technologies beyond mobile and into next-generation networks and data centers.

Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR) shares moved up 0.69% in last trading session and ended the day at $5.83. PBR Gross Margin is 30.10% and its has a return on assets of -4.00%. Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR) quarterly performance is 28.70%.

Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR) had its target price decreased by equities research analysts at Simmons to $2.00 in a research note issued to investors on Friday, StockTargetPrices.com reports. Simmons’ target price would suggest a potential downside of 62.96% from the company’s previous close.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) caters to the Healthcare space. It has a net profit margin of 0.80% and weekly performance is 4.70%. On the last day of trading company shares ended up at $50.31. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) distance from 50-day simple moving average (SMA50) is 9.12%.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) had its “buy” rating reaffirmed by analysts at Nomura. They now have a $100.00 price target on the stock.


Leave a Reply

Your email address will not be published. Required fields are marked *